Clinical Trial Update: Alemtuzumab for ANCA Associated Refractory Vasculitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating alemtuzumab for ANCA-associated refractory vasculitis; the study includes microscopic polyangiitis and granulomatosis w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Vasculitis, Microscopic Polyangiitis | Phase 4 | Status: UNKNOWN